In_IN Vitro_NP Selection_NP of_IN Resistance_NP in_IN Haemophilus_NP influenzae_NP by_IN Amoxicillin-Clavulanate_NP ,_, Cefpodoxime_NP ,_, Cefprozil_NP ,_, Azithromycin_NP ,_, and_CC Clarithromycin_NP Abilities_NP of_IN amoxicillin-clavulanate_NN ,_, cefpodoxime_NN ,_, cefprozil_NN ,_, azithromycin_NN ,_, and_CC clarithromycin_NN to_TO select_VB resistant_JJ mutants_NNS of_IN Haemophilus_NP influenzae_NP were_VBD tested_VBN by_IN multistep_NN and_CC single-step_VB methodologies_NNS ._SENT For_IN multistep_NN studies_NNS ,_, 10_CD random_JJ strains_NNS were_VBD tested_VBN :_: 5_CD of_IN these_DT were_VBD beta-lactamase_NN positive_JJ ._SENT After_IN 50_CD daily_JJ subcultures_NNS in_IN amoxicillin-clavulanate_NN ,_, MICs_NP did_VBD not_RB increase_VB more_RBR than_IN fourfold_RB ._SENT However_RB ,_, cefprozil_NP MICs_NP increased_VBD eightfold_RB for_IN one_CD strain_NN ._SENT Clarithromycin_NP and_CC azithromycin_NP gave_VBD a_DT >4-fold_NN increase_NN in_IN 8_CD and_CC 10_CD strains_NNS after_IN 14_CD to_TO 46_CD and_CC 20_CD to_TO 50_CD days_NNS ,_, respectively_RB ._SENT Mutants_NNS selected_VBN by_IN clarithromycin_NN and_CC azithromycin_NN were_VBD associated_VBN with_IN mutations_NNS in_IN 23S_JJ rRNA_NN and_CC ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP ._SENT Three_CD mutants_NNS selected_VBN by_IN clarithromycin_NN or_CC azithromycin_NN had_VBD alterations_NNS in_IN ribosomal_JJ protein_NN L4_NP ,_, while_IN five_CD had_VBD alterations_NNS in_IN ribosomal_JJ protein_NN L22_NP ._SENT Two_CD mutants_NNS selected_VBN by_IN azithromycin_NN had_VBD mutations_NNS in_IN the_DT gene_NN encoding_VBG 23S_JJ rRNA_NNS :_: one_CD at_IN position_NN 2058_CD and_CC the_DT other_JJ at_IN position_NN 2059_CD (_( Escherichia_NP coli_NNS numbering_VBG )_) ,_, with_IN replacement_NN of_IN A_DT by_IN G._NP One_CD clone_NN selected_VBN by_IN clarithromycin_NN became_VBD hypersusceptible_JJ to_TO macrolides_NNS ._SENT In_IN single-step_VB studies_NNS azithromycin_NN and_CC clarithromycin_NN had_VBD the_DT highest_JJS mutation_NN rates_NNS ,_, while_IN amoxicillin-clavulanate_NN had_VBD the_DT lowest_JJS ._SENT All_DT resistant_JJ clones_NNS were_VBD identical_JJ to_TO parents_NNS as_IN observed_VBN by_IN pulsed-field_JJ gel_NN electrophoresis_NN ._SENT The_DT MICs_NN of_IN azithromycin_NN for_IN azithromycin-resistant_JJ clones_NNS were_VBD 16_CD to_TO >128_JJ mug/ml_NN ,_, and_CC those_DT of_IN clarithromycin_NN for_IN clarithromycin-resistant_JJ clones_NNS were_VBD 32_CD to_TO >128_JJ mug/ml_NN in_IN multistep_NN studies_NNS ._SENT For_IN strains_NNS selected_VBN by_IN azithromycin_NN ,_, the_DT MICs_NN of_IN clarithromycin_NN were_VBD high_JJ and_CC vice_JJ versa_RB ._SENT After_IN 50_CD daily_JJ subcultures_NNS in_IN the_DT presence_NN of_IN drugs_NNS ,_, MICs_NNS of_IN amoxicillin-clavulanate_NN and_CC cefpodoxime_NN against_IN H._NP influenzae_NP did_VBD not_RB rise_VB more_RBR than_IN fourfold_RB ,_, in_IN contrast_NN to_TO cefprozil_NN ,_, azithromycin_NN ,_, and_CC clarithromycin_NP ,_, whose_WP$ MICs_NNS rose_VBD to_TO variable_JJ degrees_NNS ._SENT Haemophilus_NP influenzae_NP is_VBZ a_DT major_JJ cause_NN ,_, together_RB with_IN Streptococcus_NP pneumoniae_NP and_CC Moraxella_NP catarrhalis_NP ,_, of_IN community-acquired_JJ respiratory_JJ infections_NNS in_IN children_NNS and_CC adults_NNS ,_, including_VBG pneumonia_NN ,_, acute_JJ exacerbations_NNS of_IN chronic_JJ bronchitis_NN ,_, sinusitis_NN ,_, and_CC otitis_NN media_NNS ._SENT In_IN countries_NNS such_JJ as_IN the_DT United_NP States_NPS where_WRB the_DT H._NP influenzae_NP type_NN b_NN vaccine_NN is_VBZ widely_RB used_VBN ,_, untypeable_JJ H._NP influenzae_NP strains_NNS cause_VBP the_DT majority_NN of_IN infections_NNS ._SENT The_DT major_JJ resistance_NN mechanism_NN in_IN H._NP influenzae_NP is_VBZ beta-lactamase_NN production_NN (_( TEM-1_NP ,_, ROB-1_NP )_) ._SENT A_DT recent_JJ study_NN in_IN the_DT United_NP States_NPS has_VBZ documented_VBN the_DT incidence_NN of_IN beta-lactamase_NN production_NN in_IN 1,676_CD H._NP influenzae_NP strains_NNS isolated_VBN throughout_IN the_DT United_NP States_NPS to_TO be_VB 41.6_CD %_NN ._SENT The_DT incidence_NN of_IN beta-lactamase-negative_JJ ampicillin-resistant_NN (_( BLNAR_NP )_) strains_NNS in_IN the_DT United_NP States_NPS is_VBZ <1_JJ %_NN ._SENT Of_IN available_JJ beta-lactams_NNS for_IN treatment_NN of_IN infections_NNS caused_VBN by_IN this_DT organism_NN ,_, cefixime_NN and_CC cefpodoxime_NN are_VBP the_DT most_RBS active_JJ from_IN a_DT potency_NN as_RB well_RB as_IN a_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ point_NN of_IN view_NN ,_, followed_VBN by_IN amoxicillin-clavulanate_NN ,_, cefuroxime_NN ,_, and_CC cefdinir_NN ._SENT Other_JJ oral_JJ cephalosporins_NNS such_JJ as_IN cefprozil_NN ,_, cefaclor_NN ,_, and_CC loracarbef_NN are_VBP less_RBR active_JJ against_IN these_DT organisms_NNS ._SENT Among_IN macrolides_NNS and_CC azalides_NNS ,_, azithromycin_NN yields_VBZ the_DT lowest_JJS MIC_NN for_IN H._NP influenzae_NP ,_, followed_VBN by_IN erythromycin_NN and_CC clarithromycin_NN ._SENT However_RB ,_, the_DT pharmacokinetic_JJ and_CC pharmacodynamic_JJ properties_NNS of_IN these_DT compounds_NNS cast_VBD doubt_NN on_IN their_PP$ clinical_JJ efficacy_NN against_IN H._NP influenzae_NP ._SENT It_PP is_VBZ well_RB known_VBN that_IN antimicrobial_JJ abuse_NN leads_VBZ to_TO development_NN of_IN resistance_NN ._SENT Baquero_NP has_VBZ postulated_VBN that_DT abuse_NN of_IN azithromycin_NN and_CC clarithromycin_NN has_VBZ played_VBN an_DT important_JJ part_NN in_IN the_DT development_NN of_IN macrolide_NN resistance_NN in_IN S._NP pneumoniae_NNS in_IN Spain_NP ,_, Italy_NP ,_, and_CC France_NP ._SENT The_DT present_JJ study_NN attempts_NNS to_TO shed_VB further_JJR light_NN on_IN this_DT phenomenon_NN in_IN H._NP influenzae_NP by_IN using_VBG single_JJ and_CC multistep_NN resistance_NN selection_NN studies_NNS to_TO examine_VB the_DT effect_NN of_IN amoxicillin-clavulanate_NN ,_, cefpodoxime_NN ,_, cefprozil_NN ,_, azithromycin_NN ,_, and_CC clarithromycin_NN ._SENT Bacteria_NNS ._SENT |_SYM Ten_CD recent_JJ clinical_JJ isolates_NNS of_IN untypeable_JJ H._NP influenzae_NP were_VBD tested_VBN ._SENT Of_IN these_DT ,_, five_CD were_VBD beta-lactamase_JJ positive_JJ (_( by_IN Cefinase_NP disk_NN methodology_NN ;_: BBL_NP Microbiology_NP Systems_NP ,_, Cockeysville_NP ,_, Md._NP )_) and_CC five_CD were_VBD beta-lactamase_NN negative_JJ ._SENT Strains_NNS were_VBD stored_VBN in_IN double-strength_JJ skim_NN milk_NN (_( Difco_NP Laboratories_NP ,_, Detroit_NP ,_, Mich._NP )_) at_IN -70C_NN before_IN testing_NN and_CC examined_VBD for_IN purity_NN throughout_IN the_DT study_NN by_IN culture_NN and_CC Gram_NP stain_NN methods_NNS ._SENT MIC_JJ methodology_NN and_CC antimicrobials_NNS ._SENT |_SYM Microdilution_NP MICs_NP of_IN all_DT strains_NNS were_VBD determined_VBN as_IN recommended_VBN by_IN the_DT NCCLS_NP using_VBG freshly_RB prepared_JJ Haemophilus_NP test_NN medium_NN (_( HTM_NP )_) ,_, with_IN inoculum_NN checks_NNS performed_VBN in_IN each_DT case_NN ._SENT Standard_JJ quality_NN control_NN strains_NNS were_VBD included_VBN in_IN each_DT run_NN ._SENT Trays_NNS were_VBD incubated_VBN for_IN 16_CD to_TO 20_CD h_NN in_IN ambient_JJ air_NN ._SENT Drugs_NNS were_VBD obtained_VBN from_IN their_PP$ respective_JJ manufacturers_NNS ._SENT Multistep_NN mutation_NN studies_NNS ._SENT |_SYM The_DT method_NN previously_RB used_VBN by_IN our_PP$ group_NN for_IN pneumococci_NNS was_VBD modified_VBN as_RB follows_VBZ ._SENT Serial_JJ passages_NNS in_IN freshly_RB prepared_VBN HTM_NP were_VBD performed_VBN daily_RB for_IN each_DT strain_NN in_IN subinhibitory_JJ concentrations_NNS of_IN all_DT antimicrobials_NNS ._SENT For_IN each_DT subsequent_JJ daily_JJ passage_NN ,_, an_DT inoculum_NN was_VBD taken_VBN from_IN the_DT tube_NN containing_VBG antimicrobial_JJ at_IN 1_CD to_TO 2_CD dilutions_NNS below_IN the_DT MIC_NN ._SENT The_DT latter_JJ inoculum_NN was_VBD used_VBN to_TO determine_VB the_DT next_JJ MIC_NN ._SENT Daily_JJ passages_NNS were_VBD performed_VBN until_IN a_DT significant_JJ increase_NN (_( more_JJR than_IN fourfold_RB )_) was_VBD obtained_VBN ._SENT A_DT minimum_NN of_IN 14_CD passages_NNS were_VBD performed_VBN in_IN each_DT case_NN ._SENT For_IN cefprozil_NN ,_, three_CD beta-lactamase-positive_JJ strains_NNS for_IN which_WDT the_DT MICs_NP were_VBD 128_CD were_VBD not_RB tested_VBN ._SENT The_DT maximal_JJ number_NN of_IN passages_NNS was_VBD 50_CD ._SENT Control_NP MICs_NP were_VBD also_RB determined_VBN daily_RB in_IN the_DT original_JJ strain_NN without_IN serial_JJ passages_NNS ._SENT Stability_NN of_IN the_DT acquired_VBN resistance_NN was_VBD determined_VBN after_IN 10_CD daily_JJ passages_NNS of_IN the_DT clone_NN on_IN chocolate_NN agar_NN (_( BBL_NP )_) without_IN antibiotics_NNS ._SENT Single-step_VB mutations_NNS ._SENT |_SYM The_DT frequency_NN of_IN spontaneous_JJ single-step_VBP mutations_NNS was_VBD determined_VBN by_IN spreading_VBG approximately_RB 1010_CD CFU/ml_NN in_IN 100-mul_NP aliquots_NNS on_IN HTM_NP plates_NNS containing_VBG one_CD ,_, two_CD ,_, four_CD ,_, and_CC eight_CD times_NNS the_DT MIC_NN of_IN each_DT compound_NN ._SENT After_IN 24_CD to_TO 72_CD h_NN of_IN incubation_NN ,_, resistant_JJ colonies_NNS were_VBD confirmed_VBN by_IN replica_NN plating_NN on_IN media_NNS with_IN antibiotics_NNS ._SENT The_DT resistance_NN frequency_NN was_VBD calculated_VBN as_IN the_DT number_NN of_IN resistant_JJ colonies_NNS per_IN inoculum_NN ._SENT Strains_NNS 4_CD ,_, 5_CD ,_, and_CC 7_CD ,_, for_IN which_WDT the_DT MIC_NN of_IN cefprozil_NN was_VBD 128_CD ,_, were_VBD not_RB tested_VBN for_IN single-step_VB mutation_NN for_IN this_DT antibiotic_NN ._SENT Determination_NN of_IN macrolide_NN and_CC penicillin_NN resistance_NN mechanisms_NNS ._SENT |_SYM Presence_NN of_IN known_VBN resistance_NN genes_NNS for_IN macrolides_NNS mef(A/E)_JJ ,_, erm(B)_JJ ,_, erm(A)_NN [_SYM subclass_NN erm(TR)_NN ]_SYM ,_, and_CC ere(A)_NN was_VBD tested_VBN by_IN PCR_NP as_RB described_VBD previously_RB ._SENT Alterations_NNS in_IN the_DT genes_NNS coding_VBG for_IN 23S_JJ rRNA_NN and_CC ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP were_VBD verified_VBN by_IN sequencing_VBG of_IN these_DT genes_NNS after_IN amplification_NN by_IN PCR_NP ._SENT The_DT sequences_NNS for_IN 23S_JJ rRNA_NN and_CC ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP in_IN H._NP influenzae_NP were_VBD obtained_VBN from_IN The_DT Institute_NP for_IN Genomic_NP Research_NP website_NN ._SENT Specific_JJ primers_NNS used_VBN to_TO amplify_VB the_DT region_NN involved_VBN in_IN the_DT peptidyl-transferase_NN center_NN of_IN 23S_JJ rRNA_NN were_VBD HF23-1_NP (_( 5'CGGCGGCCGTAACTATAACG3_NP '_POS )_) and_CC HF23-2_NP (_( 5'GATGTGATGAGCCGACATCG3_NP '_POS )_) ,_, which_WDT amplify_VBP the_DT region_NN from_IN positions_NNS 1902_CD to_TO 2520_CD in_IN 23S_JJ rRNA_NNS (_( H._NP influenzae_NP numbering_VBG )_) ._SENT Specific_JJ primers_NNS were_VBD designed_VBN to_TO amplify_VB entire_JJ genes_NNS that_WDT code_VBP for_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP ._SENT The_DT L22_NP gene_NN was_VBD amplified_VBN with_IN primers_NNS HL22-1_JJ (_( 5'CGGCAGATAAGAAAGCTAAG3_JJ '_'' )_) and_CC HL22-2_NP (_( 5'TGGATGTACTTTTTGACCC3_NP '_POS )_) ._SENT The_DT L4_NP gene_NN was_VBD amplified_VBN with_IN primers_NNS HL4-1_JJ (_( 5'TTAAGCCGGCAGTTAAAGC3_JJ '_'' )_) and_CC HF4-2_NP (_( 5'CACTTAGCAAACGTTCTTG3_NP )_) ._SENT All_DT PCRs_NN were_VBD done_VBN as_RB follows_VBZ :_: 1_CD cycle_NN of_IN 94C_NN (_( 5_CD min_NN )_) ;_: 35_CD cycles_NNS of_IN 94C_NN (_( 1_CD min_NN )_) ,_, 50C_NP (_( 1_CD min_NN )_) ,_, and_CC 72C_NP (_( 1_CD min_NN )_) ;_: and_CC 1_CD cycle_NN of_IN 72C_NP (_( 7_CD min_NN )_) ._SENT Mutations_NNS in_IN the_DT penicillin_NN binding_JJ protein_NN PBP_NP 3_CD were_VBD investigated_VBN in_IN beta-lactam-resistant_JJ mutants_NNS by_IN amplification_NN of_IN the_DT ftsI_NN gene_NN as_IN described_VBN by_IN Ubukata_NP et_FW al._FW ._SENT The_DT PCR_NP products_NNS after_IN amplification_NN of_IN the_DT 23S_JJ rRNA_NN ,_, L22_NP ,_, L4_NP ,_, and_CC fstI_NN genes_NNS were_VBD purified_VBN using_VBG a_DT QIAquick_NP PCR_NP purification_NN kit_NN (_( QIAGEN_NP ,_, Valencia_NP ,_, Calif._NP )_) and_CC sequenced_JJ using_VBG an_DT Applied_NP Biosystems_NP model_NN 373_CD DNA_NN sequencer_NN ._SENT PFGE_NP ._SENT |_SYM All_DT strains_NNS were_VBD tested_VBN by_IN pulsed-field_JJ gel_NN electrophoresis_NN (_( PFGE_NP )_) before_IN and_CC after_IN resistance_NN selection_NN ._SENT PFGE_NP was_VBD performed_VBN using_VBG a_DT CHEF_NP DR_NP III_NP apparatus_NN (_( Bio-Rad_NP ,_, Hercules_NP ,_, Calif._NP )_) as_RB described_VBD previously_RB ._SENT Transformation_NN ._SENT |_SYM Total_NP DNA_NP was_VBD extracted_VBN from_IN mutant_JJ H._NP influenzae_NP strains_NNS and_CC used_VBN for_IN transformation_NN of_IN the_DT H._NP influenzae_NP Rd_NP (_( ATCC_NP 51907_CD )_) strain_NN as_RB described_VBD previously_RB by_IN Barcak_NP et_FW al._FW ._SENT Transformants_NNS were_VBD selected_VBN on_IN brain_NN heart_NN infusion_NN agar_NN (_( Becton_NP Dickinson_NP ,_, Cockeysville_NP ,_, Md._NP )_) ,_, supplemented_VBN with_IN hemin_NN (_( 2_CD mug/ml_NN )_) and_CC NAD_NN (_( 2_CD mug/ml_NN )_) (_( sBHI_NP )_) ,_, that_WDT contained_VBD erythromycin_NN (_( 15_CD mug/ml_NN )_) ._SENT Multistep_NN resistance_NN selection_NN ._SENT |_SYM The_DT results_NNS of_IN multistep_NN resistance_NN selection_NN experiments_NNS are_VBP shown_VBN in_IN Table_NP ._SENT After_IN 50_CD daily_JJ subcultures_NNS in_IN amoxicillin-clavulanate_NN ,_, MICs_NP did_VBD not_RB rise_VB more_RBR than_IN fourfold_RB ,_, and_CC the_DT highest_JJS MIC_NN was_VBD 4_CD mug/ml_NN ._SENT After_IN 50_CD days_NNS ,_, the_DT MICs_NN of_IN cefpodoxime_NN for_IN two_CD strains_NNS rose_VBD to_TO the_DT level_NN seen_VBN in_IN low-BLNAR_JJ strains_NNS ,_, with_IN a_DT fourfold_JJ increase_NN to_TO 0.25_CD mug/ml_NN ._SENT These_DT strains_NNS were_VBD not_RB analyzed_VBN further_RBR ,_, because_IN they_PP did_VBD not_RB meet_VB the_DT mutant_JJ selection_NN criteria_NNS (_( >4-fold_NN increase_NN )_) and_CC remained_VBD susceptible_JJ according_VBG to_TO the_DT NCCLS_NP breakpoint_NN of_IN 2.0_CD mug/ml_NN ._SENT Cefprozil_NP could_MD not_RB be_VB tested_VBN for_IN three_CD beta-lactamase-positive_JJ strains_NNS for_IN which_WDT the_DT MICs_NP were_VBD 128_CD mug/ml_NN ,_, and_CC one_CD of_IN seven_CD strains_NNS tested_VBN yielded_VBD higher_JJR MICs_NNS ._SENT Only_RB one_CD beta-lactamase-negative_NN strain_NN yielded_VBD a_DT >4-fold_NN increase_NN after_IN 32_CD days_NNS and_CC became_VBD resistant_JJ (_( MIC_JJ >=32_NN mug/ml_NN )_) ._SENT The_DT MIC_NN for_IN this_DT strain_NN was_VBD 4_CD mug/ml_NN and_CC became_VBD 64_CD mug/ml_NN after_IN selection_NN ._SENT Azithromycin_NP gave_VBD a_DT >4-fold_NN increase_NN in_IN MICs_NP for_IN all_DT 10_CD strains_NNS after_IN 20_CD to_TO 50_CD days_NNS ,_, and_CC clarithromycin_NP gave_VBD a_DT >4-fold_NN increase_NN in_IN MICs_NP for_IN 8_CD of_IN 10_CD strains_NNS after_IN 14_CD to_TO 46_CD days_NNS ._SENT Parent_NN 1_CD strain_NN yielded_VBD two_CD clarithromycin-resistant_JJ clones_NNS :_: one_PP became_VBD hypersusceptible_JJ to_TO macrolides_NNS during_IN the_DT 10_CD days_NNS of_IN daily_JJ drug-free_JJ subcultures_NNS ._SENT The_DT MICs_NN of_IN erythromycin_NN ,_, azithromycin_NP ,_, clarithromycin_NP ,_, clindamycin_NN ,_, and_CC quinupristin-dalfopristin_NN for_IN this_DT hypersusceptible_JJ mutant_NN were_VBD 0.5_CD ,_, 0.06_CD ,_, 0.12_CD ,_, 0.06_CD ,_, and_CC 0.06_CD mug/ml_NN ,_, instead_RB of_IN 8_CD ,_, 2_CD ,_, 8_CD ,_, 32_CD ,_, and_CC 2_CD mug/ml_NN ,_, respectively_RB ,_, in_IN the_DT parent_NN strain_NN ._SENT All_DT resistant_JJ clones_NNS were_VBD identical_JJ to_TO parents_NNS by_IN PFGE_NP ._SENT MICs_NNS of_IN azithromycin_NN for_IN azithromycin-resistant_JJ clones_NNS were_VBD 16_CD to_TO >128_JJ mug/ml_NN ,_, and_CC those_DT of_IN clarithromycin_NN for_IN clarithromycin-resistant_JJ clones_NNS were_VBD 32_CD to_TO >128_JJ mug/ml_NN ._SENT For_IN strains_NNS selected_VBN by_IN azithromycin_NN ,_, the_DT MICs_NN of_IN clarithromycin_NN were_VBD high_JJ and_CC vice_JJ versa_RB ,_, but_CC for_IN the_DT one_CD strain_NN selected_VBN by_IN a_DT beta-lactam_NN (_( cefprozil_NN )_) the_DT azithromycin_NN and_CC clarithromycin_NN MICs_NNS were_VBD the_DT same_JJ as_IN those_DT for_IN the_DT parent_NN strain_NN ._SENT Single-step_VB mutations_NNS ._SENT |_SYM Single-step_JJ mutation_NN results_NNS are_VBP shown_VBN in_IN Table_NP ._SENT The_DT mutation_NN frequencies_NNS for_IN cultures_NNS grown_VBN with_IN MICs_NP of_IN the_DT antimicrobials_NNS were_VBD 2.0_CD x_SYM 10-3_CD to_TO 2.0_CD x_NN 10-9_CD (_( clarithromycin_NN )_) ,_, 6.0_CD x_SYM 10-4_CD to_TO 1.3_CD x_NN 10-9_CD (_( azithromycin_NN )_) ,_, 1.7_CD x_SYM 10-7_CD to_TO <2.5_NN x_NN 10-10_CD (_( cefprozil_NN for_IN seven_CD strains_NNS tested_VBD )_) ,_, 1.5_CD x_SYM 10-7_CD to_TO <1.0_NN x_NN 10-10_CD (_( cefpodoxime_NN )_) ,_, and_CC <6.7_JJ x_NN 10-10_CD to_TO <1.0_x 128_CD mug/ml_NN ._SENT Three_CD strains_NNS selected_VBN by_IN clarithromycin_NN had_VBD deletions_NNS or_CC one-amino-acid_JJ substitutions_NNS in_IN the_DT highly_RB conserved_VBN region_NN of_IN ribosomal_JJ protein_NN L4_NP ._SENT Mutant_JJ C3_NP had_VBD a_DT replacement_NN of_IN Gly_NP by_IN Asp_NP at_IN position_NN 65_CD ._SENT Mutant_NN 5_CD had_VBD a_DT deletion_NN of_IN two_CD amino_NN acids_NNS ,_, Gly_NP and_CC Arg_NP ,_, after_IN position_NN 65_CD ,_, and_CC mutant_JJ C10_NP had_VBD a_DT change_NN of_IN Gly_NP to_TO Ala_NP at_IN position_NN 53_CD and_CC a_DT deletion_NN of_IN Arg_NP and_CC Ala_NP after_IN position_NN 66_CD in_IN ribosomal_JJ protein_NN L4_NP ._SENT These_DT mutations_NNS in_IN L4_NP were_VBD associated_VBN with_IN a_DT >4-fold_NN increase_NN in_IN the_DT MICs_NN of_IN clarithromycin_NN and_CC azithromycin_NN ._SENT The_DT alterations_NNS in_IN ribosomal_JJ protein_NN L22_NP were_VBD in_IN the_DT highly_RB conserved_VBN region_NN of_IN this_DT protein_NN by_IN substitution_NN of_IN one_CD amino_NN acid_NN ,_, or_CC by_IN amino_NN acid_NN insertions_NNS or_CC deletions_NNS ._SENT Mutants_NNS C1_NP and_CC A6_NP had_VBD one_CD amino_NN acid_JJ change_NN at_IN positions_NNS 88_CD and_CC 93_CD :_: Arg_NN to_TO Pro_NP and_CC Ala_NP to_TO Glu_NP ,_, respectively_RB ._SENT The_DT mutant_JJ C2_NP had_VBD seven_CD amino_NN acid_NN insertions_NNS after_IN position_NN 72_CD in_IN L22_NP ._SENT Mutants_NNS C8_NP and_CC A3_NP had_VBD one_CD and_CC three_CD amino_NN acid_NN deletions_NNS ,_, respectively_RB ,_, after_IN position_NN 82_CD ._SENT The_DT increase_NN in_IN MICs_NP of_IN clarithromycin_NN and_CC azithromycin_NN for_IN mutants_NNS with_IN L22_NP alterations_NNS was_VBD at_IN least_JJS eightfold_JJ ._SENT Total_NP DNAs_NP from_IN C1_NP with_IN the_DT L22_NP mutation_NN and_CC C10_NN with_IN the_DT L4_NP mutation_NN were_VBD used_VBN for_IN transformation_NN of_IN H._NP influenzae_NP Rd_NP ._SENT After_IN transformation_NN resistant_NN strains_NNS were_VBD selected_VBN on_IN sBHI_NN agar_NN with_IN erythromycin_NN (_( 15_CD mug/ml_NN )_) ._SENT Two_CD transformants_NNS were_VBD studied_VBN further_RBR ._SENT Transformants_NP C1/Rd_NP (_( L22_NP )_) and_CC C10/Rd_NP (_( L4_NP )_) had_VBD the_DT same_JJ PFGE_NN pattern_NN as_IN the_DT Rd_JJ strain_NN after_IN digestion_NN by_IN SmaI_NP ._SENT The_DT MICs_NN of_IN erythromycin_NN for_IN Rd_JJ strains_NNS rose_VBD from_IN 2_CD mug/ml_NN to_TO 64_CD and_CC 32_CD mug/ml_NN after_IN transformation_NN with_IN total_JJ DNA_NN from_IN mutants_NNS C1_NP and_CC C10_NP ,_, respectively_RB ._SENT The_DT sequence_NN analysis_NN of_IN the_DT genes_NNS coding_VBG for_IN 23S_JJ rRNA_NN and_CC ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP were_VBD amplified_VBN from_IN transformants_NNS and_CC the_DT Rd_JJ strain_NN and_CC was_VBD sequenced_JJ ._SENT The_DT transformants_NNS C1/Rd_NP and_CC C10/Rd_NP had_VBD the_DT same_JJ mutations_NNS as_IN the_DT mutants_NNS C1_NP and_CC C10_NP ,_, respectively_RB ._SENT Among_IN 18_CD resistant_JJ mutant_JJ strains_NNS selected_VBN by_IN azithromycin_NN and_CC clarithromycin_NN ,_, no_DT modification_NN was_VBD found_VBN in_IN ribosomal_JJ proteins_NNS L4_NP or_CC L22_NP or_CC the_DT studied_VBN portion_NN of_IN 23S_JJ rRNA_NN for_IN eight_CD strains_NNS ._SENT These_DT strains_NNS are_VBP currently_RB being_VBG studied_VBN for_IN their_PP$ resistance_NN mechanisms_NNS ._SENT Three_CD randomly_RB selected_VBD single-step_VB mutants_NNS ,_, selected_VBN at_IN two_CD times_NNS MIC_JJ by_IN azithromycin_NN and_CC clarithromycin_NN ,_, were_VBD analyzed_VBN for_IN alterations_NNS in_IN 23S_JJ rRNA_NN ,_, and_CC ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP ._SENT Strains_NNS selected_VBN by_IN azithromycin_NN from_IN parents_NNS 6_CD and_CC 8_CD had_VBD deletions_NNS in_IN ribosomal_JJ protein_NN L22_NP :_: two_CD amino_NN acids_NNS ,_, Arg_NP and_CC Ile_NP ,_, at_IN positions_NNS 95_CD and_CC 96_CD from_IN strain_NN 6_CD and_CC Asp_NP and_CC Glu_NP at_IN positions_NNS 77_CD and_CC 78_CD from_IN strain_NN 8_CD ,_, were_VBD deleted_VBN ._SENT No_DT modification_NN was_VBD found_VBN in_IN the_DT other_JJ strains_NNS ._SENT Mechanism_NN of_IN resistance_NN to_TO cefprozil_NN ._SENT |_SYM The_DT gene_NN ftsI_NN that_IN codes_NNS for_IN PBP_NP 3_CD from_IN parent_NN 1_CD and_CC the_DT mutant_JJ strain_NN selected_VBN by_IN cefprozil_NN were_VBD amplified_VBN and_CC sequenced_VBN ._SENT The_DT analysis_NN of_IN these_DT sequences_NNS and_CC alignment_NN of_IN deduced_VBN amino_NN acids_NNS showed_VBD two_CD mutations_NNS ,_, which_WDT led_VBD to_TO Ala-to-Val_NP and_CC Ser-to-Asn_NP substitutions_NNS at_IN positions_NNS 271_CD and_CC 357_CD ,_, respectively_RB ._SENT These_DT mutations_NNS were_VBD associated_VBN with_IN a_DT 16-fold_NN increase_NN in_IN the_DT cefprozil_NN MIC_NN ;_: however_RB ,_, the_DT activity_NN of_IN amoxicillin-clavulanate_NN and_CC cefpodoxime_NN was_VBD not_RB affected_VBN ._SENT FIG._NN 1_CD ._SENT |_SYM Alignment_NN of_IN deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT highly_RB conserved_VBN region_NN of_IN ribosomal_JJ protein_NN L4_NP from_IN E._NP coli_NNS ,_, Salmonella_NP enterica_NP Alignment_NP of_IN deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT highly_RB conserved_VBN region_NN of_IN ribosomal_JJ protein_NN L4_NP from_IN E._NP coli_NNS ,_, Salmonella_NP enterica_NP serovar_NP Typhimurium_NP ,_, and_CC H._NP influenzae_NP and_CC parent_NN strains_NNS and_CC macrolide-resistant_JJ mutant_JJ H._NP influenzae_NP strains_NNS obtained_VBD by_IN in_IN vitro_NN multistep_NN resistance_NN selection_NN ._SENT Alterations_NNS are_VBP indicated_VBN in_IN boldface_JJ type_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Alignment_NN of_IN deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT highly_RB conserved_VBN region_NN of_IN ribosomal_JJ protein_NN L22_NP from_IN E._NP coli_NNS ,_, S._NP enterica_NP Alignment_NP of_IN deduced_VBN amino_NN acid_NN sequences_NNS of_IN the_DT highly_RB conserved_VBN region_NN of_IN ribosomal_JJ protein_NN L22_NP from_IN E._NP coli_NNS ,_, S._NP enterica_NP Typhimurium_NP ,_, and_CC H._NP influenzae_NP and_CC the_DT parent_NN strains_NNS and_CC macrolide-resistant_JJ mutant_JJ H._NP influenzae_NP strains_NNS obtained_VBD by_IN in_IN vitro_NN multistep_NN resistance_NN selection_NN ._SENT Alterations_NNS are_VBP indicated_VBN in_IN boldface_JJ type_NN ._SENT TABLE_NN 1_CD |_SYM Multistep_JJ resistance_NN selection_NN studies_NNS TABLE_NP 2_CD |_SYM Frequencies_NNS of_IN single-step_VBP mutation_NN for_IN 10_CD H._NP influenzae_NP strains_NNS used_VBN for_IN multistep_NN study_NN TABLE_NP 3_CD |_SYM Susceptibilities_NNS of_IN parent_NN H._NP influenzae_NP strains_NNS and_CC their_PP$ selected_JJ mutants_NNS with_IN alterations_NNS in_IN rRNA_NN 23S_JJ TABLE_NP 5_CD |_SYM Susceptibilities_NNS of_IN parent_NN H._NP influenzae_NP strains_NNS and_CC their_PP$ selected_JJ mutants_NNS with_IN alterations_NNS in_IN ribosomal_JJ protein_NN L22_NP TABLE_NP 4_CD |_SYM Susceptibilities_NNS of_IN parent_NN H._NP influenzae_NP strains_NNS and_CC their_PP$ selected_JJ mutants_NNS with_IN alterations_NNS in_IN ribosomal_JJ protein_NN L4_NP TABLE_NP 6_CD |_SYM Susceptibility_NN of_IN H._NP influenzae_NP Rd_NP strains_NNS transformed_VBN with_IN total_JJ DNA_NN from_IN C1_NP with_IN mutation_NN in_IN ribosomal_JJ protein_NN L22_NP and_CC C10_NP with_IN mutation_NN in_IN ribosomal_JJ protein_NN L4_NP The_DT main_JJ mechanism_NN of_IN resistance_NN detected_VBN in_IN wild-type_NN H._NP influenzae_NP strains_NNS is_VBZ the_DT production_NN of_IN beta-lactamase_NN ,_, with_IN an_DT overall_JJ prevalence_NN of_IN 13.4_CD %_NN in_IN Europe_NP and_CC up_RB to_TO 41.6_CD %_NN in_IN the_DT United_NP States_NPS ._SENT In_IN Japan_NP ,_, the_DT prevalence_NN of_IN beta-lactamase_NN production_NN is_VBZ low_JJ (_( 13.9_CD %_NN )_) ._SENT However_RB ,_, the_DT prevalence_NN of_IN BLNAR_NP strains_NNS is_VBZ 28.8_CD %_NN ,_, while_IN in_IN the_DT United_NP States_NPS and_CC Europe_NP this_DT phenotype_NN is_VBZ rare_JJ (_( <1%)_. 128.0_CD mug/ml_NN ._SENT Such_JJ high_JJ MICs_NNS are_VBP not_RB commonly_RB seen_VBN in_IN clinical_JJ H._NP influenzae_NP isolates_VBZ ,_, and_CC their_PP$ clinical_JJ significance_NN is_VBZ unclear_JJ at_IN the_DT present_JJ time_NN ._SENT To_TO our_PP$ knowledge_NN ,_, no_DT resistance_NN mechanisms_NNS have_VBP been_VBN described_VBN for_IN highly_RB macrolide-resistant_JJ H._NP influenzae_NP strains_NNS ._SENT In_IN this_DT study_NN we_PP characterized_VBD mutations_NNS in_IN 23S_JJ rRNA_NN and_CC in_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP in_IN H._NP influenzae_NP mutants_NNS for_IN which_WDT the_DT macrolide_NN and_CC azalide_NN MICs_NNS are_VBP high_JJ ._SENT Macrolide_NN resistance_NN as_IN a_DT result_NN of_IN alterations_NNS in_IN 23S_JJ rRNA_NNS have_VBP been_VBN found_VBN in_IN different_JJ gram-negative_JJ and_CC -positive_JJ species_NNS ._SENT For_IN two_CD resistant_JJ mutants_NNS selected_VBN by_IN exposure_NN to_TO azithromycin_NN ,_, with_IN A2059C_NP and_CC A2058G_NP mutations_NNS in_IN 23S_JJ rRNA_NN ,_, the_DT MICs_NP of_IN azithromycin_NP ,_, clarithromycin_NP ,_, erythromycin_NN ,_, and_CC clindamycin_NN were_VBD >128_JJ mug/ml_NN ._SENT The_DT mutations_NNS found_VBN in_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP were_VBD in_IN the_DT highly_RB conserved_VBN region_NN of_IN these_DT proteins_NNS (_( Fig._NN and_CC )_) ._SENT These_DT mutations_NNS probably_RB cause_VBP a_DT conformational_JJ change_NN in_IN the_DT ribosome_NN that_WDT decreases_VBZ the_DT affinity_NN of_IN macrolides_NNS ._SENT Resistance_NN as_IN a_DT result_NN of_IN mutations_NNS in_IN L4_NP and_CC L22_NP have_VBP been_VBN reported_VBN in_IN in_IN vitro_NN mutants_NNS of_IN E._NP coli_NNS ._SENT L4_JJ mutation_NN has_VBZ been_VBN detected_VBN as_IN the_DT cause_NN of_IN resistance_NN in_IN clinical_JJ isolates_NNS of_IN S._NP pneumoniae_NNS ._SENT In_IN laboratory_NN mutants_NNS of_IN S._NP pneumoniae_NNS ,_, alterations_NNS in_IN ribosomal_JJ protein_NN L4_NP and_CC L22_NP conferring_VBG resistance_NN to_TO macrolides_NNS were_VBD also_RB shown_VBN ._SENT This_DT study_NN showed_VBD that_IN mutations_NNS in_IN ribosomal_JJ proteins_NNS in_IN L4_NP and_CC L22_NP in_IN H._NP influenzae_NP were_VBD associated_VBN with_IN increases_NNS in_IN the_DT MICs_NN of_IN erythromycin_NN ,_, clarithromycin_NN ,_, and_CC azithromycin_NN and_CC contributed_VBD to_TO increases_NNS of_IN macrolide_NN MICs_NP in_IN H._NP influenzae_NP Rd_NP strain_NN ,_, as_RB observed_VBN in_IN transformation_NN studies_NNS ._SENT However_RB MICs_NP of_IN clindamycin_NN and_CC quinupristin-dalfopristin_NN were_VBD not_RB raised_VBN in_IN all_DT of_IN these_DT mutants_NNS ._SENT Susceptibility_NN to_TO quinupristin-dalfopristin_NN seems_VBZ to_TO be_VB affected_VBN by_IN alterations_NNS in_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP far_RB more_RBR than_IN to_TO clindamycin_NN ._SENT In_IN some_DT mutants_NNS a_DT fourfold_JJ decrease_NN in_IN clindamycin_NN MICs_NNS was_VBD observed_VBN ._SENT The_DT significance_NN and_CC explanation_NN for_IN these_DT lower_JJR clindamycin_NN MICs_NNS are_VBP unknown_JJ at_IN this_DT time_NN ._SENT In_IN clinical_JJ strains_NNS of_IN S._NP pneumoniae_NNS ,_, mutations_NNS in_IN L4_NP do_VBP not_RB affect_VB the_DT susceptibility_NN of_IN the_DT strains_NNS to_TO clindamycin_NN ._SENT The_DT isolation_NN of_IN an_DT H._NP influenzae_NP clone_NN that_WDT was_VBD hypersusceptible_JJ to_TO macrolides_NNS is_VBZ of_IN great_JJ interest_NN ._SENT The_DT mechanism_NN of_IN macrolide_NN susceptibility_NN in_IN this_DT hypersusceptible_JJ strain_NN is_VBZ currently_RB under_IN investigation_NN ._SENT For_IN eight_CD resistant_JJ mutants_NNS no_DT mechanism_NN of_IN resistance_NN was_VBD detected_VBN ._SENT The_DT absence_NN of_IN modifications_NNS in_IN the_DT studied_VBN portion_NN of_IN 23S_JJ rRNA_NN and_CC in_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP shows_VBZ that_IN other_JJ ribosomal_JJ regions_NNS or_CC proteins_NNS are_VBP likely_JJ to_TO be_VB involved_VBN in_IN macrolide_NN resistance_NN ._SENT Investigation_NN of_IN the_DT mechanisms_NNS of_IN resistance_NN are_VBP being_VBG conducted_VBN in_IN our_PP$ laboratory_NN ._SENT In_IN summary_NN ,_, repeated_VBD daily_JJ subcultures_NNS in_IN subinhibitory_JJ concentrations_NNS of_IN amoxicillin-clavulanate_NN and_CC cefpodoxime_NN did_VBD not_RB lead_VB to_TO development_NN of_IN resistant_JJ clones_NNS ,_, although_IN cefpodoxime_NN MICs_NNS of_IN some_DT strains_NNS rose_VBD to_TO the_DT levels_NNS seen_VBN in_IN low-BLNAR_JJ strains_NNS ._SENT Only_RB one_CD resistant_NN mutant_NN was_VBD selected_VBN by_IN cefprozil_NN from_IN a_DT beta-lactamase-negative_JJ strain_NN ._SENT Sequential_JJ subculture_NN in_IN azithromycin_NN and_CC clarithromycin_NN led_VBN to_TO extremely_RB high_JJ MICs_NNS ,_, and_CC in_IN some_DT strains_NNS these_DT increases_NNS in_IN MICs_NP were_VBD associated_VBN with_IN alterations_NNS in_IN 23S_JJ rRNA_NN ,_, or_CC in_IN ribosomal_JJ proteins_NNS L4_NP or_CC L22_NP ._SENT One_CD initially_RB resistant_JJ mutant_JJ strain_NN became_VBD hypersusceptible_JJ to_TO macrolides_NNS during_IN subculture_NN without_IN antibiotic_NN ._SENT The_DT clinical_JJ significance_NN of_IN these_DT findings_NNS is_VBZ not_RB known_VBN ,_, and_CC this_DT aspect_NN is_VBZ currently_RB being_VBG investigated_VBN by_IN our_PP$ group_NN ._SENT 